𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Cost-effectiveness of chemoprevention of breast cancer using tamoxifen in a postmenopausal US population

✍ Scribed by Joyce Noah-Vanhoucke; Linda E. Green; Tuan A. Dinh; Peter Alperin; Robert A. Smith

Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
279 KB
Volume
117
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Cost-effectiveness of switching to exeme
Cost-effectiveness of switching to exemestane versus continued tamoxifen as adjuvant therapy for postmenopausal women with primary breast cancer
✍ Nancy A. Risebrough; Shailendra Verma; Maureen Trudeau; Nicole Mittmann πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 170 KB πŸ‘ 1 views

## Abstract ## BACKGROUND. Sequential tamoxifen/exemestane therapy reportedly improves disease‐free survival in women with primary breast cancer compared with continued tamoxifen therapy. The objective of the current study was to assess the cost‐effectiveness of switching to exemestane after 2 to

Use of aromatase inhibitors in postmenop
Use of aromatase inhibitors in postmenopausal women with advanced breast cancer
✍ Roseman, Barry J.; Buzdar, Aman U.; Singletary, S. Eva πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 39 KB πŸ‘ 2 views

Surgeons have been involved in the management of metastatic breast cancer since the technique of ovarian ablation was introduced in 1896. However, as newer hormonal and chemotherapeutic regimens were developed, drug therapy gradually replaced surgery as the preferred treatment for metastatic breast

Clinical development of estrogen modulat
Clinical development of estrogen modulators for breast cancer chemoprevention in premenopausal vs. postmenopausal women
✍ Julia A. Lawrence; Phyllis B. Malpas; Caroline C. Sigman; Gary J. Kelloff πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 103 KB πŸ‘ 2 views

Tamoxifen has proven to be beneficial in the chemoprevention of breast cancer in women at increased risk for the disease. Other compounds that mediate the estrogen pathway remain to be tested for clinical efficacy. The mechanism of action, efficacy, and dose response of the estrogen modulators is de